Sichuan Huiyu Pharmaceutical Co Ltd

688553 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

10.72CNY-0.48 (-4.29%)

Price History

Full chart

Market Stats

Previous Close11.20

Open11.20

Day Range10.68 – 11.22

52-Week Range9.61 – 17.02

Volume9.69M

Market Cap8.04B

P/E (TTM)53.54

Forward P/E0.00

EPS0.24

Dividend Yield1.56%

Beta0.52

50-Day Avg11.70

200-Day Avg12.43

About

Sichuan Huiyu Pharmaceutical Co., Ltd. researches, develops, produces, and sells anti-tumor injection in China and internationally. It offers injection drug products, such as pemetrexed disodium, methrotrexate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levetiracetam concentrated solution, amifostine, levofolate calcium, thiotepa, fulvestrant, and milrinone drugs. The company also offers moroxydine sodium chloride, fluorouracil, sodium thiosulfate, acetylcysteine, nimodipine, nimodipine, dihydroxypropyltheophylline, cisatracurium besylate, cladribine, sodium carbosulfan, octreotide acetate, mesobamo, doxorubicin, leucovorin calcium, famotidine, etoposide, polymyxin B sulfate, melphalan hydrochloride, teicoplanin, epirubicin hydrochloride, gemcitabine hydrochloride, cytarabine, voriconazole, roxatidine acetate hydrochloride, and bortezomib drugs. Sichuan Huiyu Pharmaceutical Co., Ltd. was incorporated in 2010 and is headquartered in Neijiang, China.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEODr. Zhao Ding
Employees1.45K
HeadquartersBuilding 3, Neijiang, China, 641000, China
Websitehttps://www.huiyupharma.com

Leadership

Dr. Zhao DingChairman of the Board & GM · b. 1985
Mr. Lan GaoDirector & Finance Director · b. 1971
Mr. Yong Chun RenEmployee Representative Director & Deputy General Manager · b. 1968
Mr. Chun Ping ZhangDeputy GM, Secretary of the Board & Director · b. 1980
Yan Mei YuAccounting Supervisor
Mr. Gang CaiManager of Technical Department, Quality Manager & Quality Director · b. 1977
Dr. He Ping HuDirector of the Institute of Chemical Drugs of Huiyu Pharmaceutical Research Institute · b. 1977
Dr. Tao WeiDirector of Institute of Innovative Biopharmaceuticals at Huiyu Pharmaceutical Research Institute · b. 1962

Financials

Income Statement

Currency: CNY	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	13.98M	54.32M	707.08M	1.36B	1.82B	1.49B	927.08M	1.09B	998.14M
Growth (%)	-	+288.45%	+1201.68%	+92.93%	+33.69%	-18.12%	-37.92%	+18.05%	-8.79%
Cost of Revenue	12.27M	12.63M	50.37M	120.91M	160.19M	180.12M	132.75M	187.58M	203.60M
Gross Profit	1.71M	41.69M	656.70M	1.24B	1.66B	1.31B	794.32M	906.80M	998.14M
Gross Margin	12.24%	76.75%	92.88%	91.14%	91.22%	87.94%	85.68%	82.86%	100.00%
Operating Expense	85.99M	112.26M	456.84M	845.28M	1.18B	1.08B	669.95M	558.37M	1.06B
Operating Income	-84.28M	-70.57M	199.86M	398.00M	478.76M	235.45M	124.37M	348.43M	-65.05M
Operating Margin	-602.67%	-129.92%	28.27%	29.17%	26.25%	15.77%	13.42%	31.84%	-6.52%
EBITDA	-23.97M	-24.41M	233.09M	423.22M	514.39M	287.29M	198.03M	439.72M	13.38M
EBITDA Margin	-171.39%	-44.94%	32.97%	31.02%	28.21%	19.24%	21.36%	40.18%	1.34%
Net Income	-84.72M	-22.00M	176.94M	343.32M	445.86M	248.99M	139.79M	325.39M	-24.20M
Net Income Margin	-605.83%	-40.51%	25.02%	25.17%	24.45%	16.67%	15.08%	29.73%	-2.42%
R&D	22.14M	39.15M	55.62M	88.77M	248.21M	356.19M	340.76M	327.72M	302.71M
R&D as % of Total Revenue	158.34%	72.07%	7.87%	6.51%	13.61%	23.85%	36.76%	29.95%	30.33%
Interest Expense	34.21M	24.93M	14.51M	2.01M	1.26M	1.18M	7.07M	13.51M	9.78M
Interest Expense % of Total Revenue	244.62%	45.89%	2.05%	0.15%	0.07%	0.08%	0.76%	1.23%	0.98%

Balance Sheet

Currency: CNY	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	236.61M	339.31M	859.98M	1.21B	4.13B	4.28B	4.69B	5.17B	5.02B
Total Liabilities	421.94M	490.02M	451.33M	461.26M	571.01M	558.44M	911.22M	1.19B	1.27B
Total Equity	-185.32M	-150.70M	408.68M	751.48M	3.56B	3.72B	3.77B	3.98B	3.76B
Cash	4.62M	45.72M	259.14M	371.52M	1.31B	1.21B	1.78B	2.33B	2.40B
Total Debt	234.89M	204.89M	56.00M	10.98M	20.00M	55.09M	428.78M	580.28M	-
Net Debt	230.27M	159.17M	-203.14M	-360.54M	-1.29B	-1.15B	-1.35B	-1.75B	-

Cash Flow

Currency: CNY	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-13.16M	129.06M	326.22M	387.95M	446.36M	194.06M	66.93M	242.96M	90.51M
Investing Cash Flow	-1.95M	-30.62M	-278.90M	-226.09M	-1.87B	-181.03M	233.35M	270.46M	-
Financing Cash Flow	3.22M	-57.33M	165.83M	-49.29M	2.35B	-99.99M	122.30M	-86.30M	-
Capital Expenditure	7.05M	23.04M	110.00M	158.24M	433.45M	461.61M	296.72M	128.18M	105.27M
Free Cash Flow	-20.21M	106.02M	216.22M	229.71M	12.91M	-267.55M	-229.79M	114.78M	-14.76M
Dividends Paid	9.88M	48.86M	14.15M	1.87M	690.27K	89.38M	99.51M	98.14M	199.07M
FCF to OCF	153.54%	82.15%	66.28%	59.21%	2.89%	-137.87%	-343.31%	47.24%	-16.31%
Dividend Paid to FCF	-48.88%	46.08%	6.54%	0.82%	5.35%	-33.41%	-43.30%	85.50%	-1348.68%

Earnings

Report Date	Mar 31, 2022	Jun 30, 2022	Sep 30, 2022	Dec 31, 2022	Mar 31, 2023
EPS Estimate	-	-	-	-	-
EPS Actual	0.28	0.12	0.15	0.03	0.09
Surprise	-	-	-	-	-
Timing	-	-	-	-	-

Key Statistics & Ratios

Market Cap8.04B

Enterprise Value5.90B

Trailing P/E53.54

Forward P/E0.00

Price / Sales7.33

Price / Book2.14

EPS0.24

Book Value5.98

Revenue (TTM)1.10B

Gross Profit (TTM)848.47M

EBITDA155.10M

Profit Margin10.34%

Operating Margin2.06%

Return on Equity2.97%

Return on Assets0.75%

Shares Outstanding625.90M

Shares Float356.73M

Beta0.52

Dividend Yield1.56%

Dividend Rate0.20

Payout Ratio83.52%

Dividends

20261×

0.20Jun 17, 2026

20251×

0.31Jun 13, 2025

20241×

0.14Jun 24, 2024

20231×

0.16May 25, 2023

20221×

0.14Aug 22, 2022

Stock Splits

Jun 17, 20261.48:1